<?xml version="1.0" encoding="UTF-8"?>
<p>In a perfect world, the continued scale-up of mass treatment, together with the eventual integration of NTD vaccines, would lead to the global elimination of the world’s NTDs. But not so fast: We do not yet have in place a global financing mechanism to support the advanced clinical development and licensure of the most urgently needed NTD vaccines, and, unless we can figure this out, many of these vaccines may never be produced [
 <xref rid="pntd.0007872.ref023" ref-type="bibr">23</xref>]. Another major hurdle is the stark reality that in many of the poorest nations, health systems remain profoundly depleted, especially in some of the largest sub-Saharan African nations (such as DR Congo and Nigeria), where it is anticipated that 40% of the world’s extremely poor people will live by the year 2050 [
 <xref rid="pntd.0007872.ref024" ref-type="bibr">24</xref>]. A concern is that such nations might experience difficulties incorporating new and appropriate technologies.
</p>
